ORIGINAL RESEARCH. Introduction
|
|
- Hilary Casey
- 6 years ago
- Views:
Transcription
1 r 2007 British HIV Association HIV Medicine (2007), 8, ORIGINAL RESEARCH Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area E Martínez, 1 A Milinkovic, 1 E Buira, 2 E de Lazzari, 1 A León, 1 M Larrousse, 1 M Loncá, 1 M Laguno, 1 JL Blanco, 1 J Mallolas, 1 F García, 1 JM Miró 1 and JM Gatell 1 1 Infectious Diseases Unit, Institut d Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic Universitari, and 2 Programa per a la Prevenció i l Assistència de la Sida, Departament de Sanitat i Seguretat Social, Generalitat de Catalunya, Barcelona, Spain Background Since the introduction of highly active antiretroviral therapy (HAART), the incidence of death in HIV-infected patients has dramatically decreased, and causes of death other than those related to HIV infection have increased, although it is unclear how these parameters compare with those in the age-matched general population living in the same geographical region. Methods Consecutive HIV-infected adults who were prescribed HAART in our hospital were prospectively followed from January 1997 to December 2004 or until death, loss to follow-up or discontinuation of HAART. Estimations of the annual incidence and causes of death in the general population of similar age in Catalonia per calendar year in the study period were obtained and compared with those in the HIV-infected cohort. Results There were 235 deaths among the 4471 patients on HAART (5%). The incidence of mortality decreased over time in HIV-infected patients (Po0.001; w 2 test for trend), although it has remained approximately five times higher than that for the age-matched general population. AIDS-related events were the most common cause of death (n 5 95; 40%), although they significantly decreased over time (Po0.001; w 2 test for trend), whereas liver diseases (Po0.001; w 2 test for trend) and non-aids-defining infections (P ; w 2 test for trend) significantly increased over time. Infections in general (33 times higher), liver diseases (11 times higher) and non-hodgkin lymphoma (5 times higher) were overrepresented as causes of death in the HIV-infected cohort compared with the age-matched general population. Conclusions Non-AIDS-defining infectious diseases, liver diseases, and non-hodgkin lymphoma represent specific targets for efforts to further decrease mortality in HIV-infected patients receiving HAART. Keywords: antiretroviral therapy, causes, death, HIV-infected persons, incidence Received: 1 September 2006, accepted 19 January 2007 Introduction The dramatic decrease in AIDS-related mortality associated with the routine introduction of highly active antiretroviral Correspondence: Dr Esteban Martínez, Infectious Diseases Unit, Hospital Clínic, C/Villarroel 170, Barcelona, Spain. Tel: ; fax: ; esteban@fundsoriano.es therapy (HAART) in developed countries has changed consideration of HIV infection from a rapidly fatal to a chronic manageable disease [1 4]. The clinical benefit associated with HAART seems to be largely a result of its ability to produce sustained suppression of viral replication [5], and its effectiveness has increased with time [6,7]. Recent data from the observational DAD Study cohort showed that mortality in HIV-infected patients not only 251
2 252 E Martínez et al. from HIV-related causes but also from other causes, such as neoplasia and liver and heart disease, increased with immunological decline [8]. These data are in accordance with those from the largest randomized study on an antiretroviral treatment interruption trial, the SMART Study, in which deaths not only from HIV-related but also from non-hivrelated causes were significantly increased in the therapy discontinuation arm [9]. Knowledge concerning mortality in HIV-infected patients receiving HAART has been evolving as the amount of data available has increased, but the studies in which the data were obtained have several limitations. The incidence of mortality in HIV-infected persons receiving HAART may not be accurate because some cohort studies have used a combined endpoint of AIDS or death, as a result in part of lack of information on causes of death [5,6,10]. In addition, data on the causes of death in the era of HAART are scarce. Some cohort studies have distinguished generically between AIDS-related and non-aids-related causes without further details on specific causes of death [11,12], or have been limited exclusively to certain causes of death such as liver disease [13]. Other studies reporting more specifically the causes of death of HIV-infected patients have not compared them with those in the general population [14 16] or lacked combined information on the incidence of mortality [17]. As the proportion of non-hiv-related deaths has been increasing in observational cohorts, there is a need to define and standardize causes of death more effectively and to compare them with those in the general population of similar age in order that the excess mortality attributable to any one cause may be identified [12]. This information would help health policy makers and clinicians to design strategies to diminish further the mortality of HIV-infected persons receiving HAART [18]. We aimed to analyse the incidence and causes of death in HIV-infected adults treated with HAART and cared for in our hospital, and to compare the results with those for the general population of similar age living in the same geographical region. Methods From January 1997 to December 2004, consecutive HIVinfected adults (at least 16 years old) who had HAART prescribed at the Infectious Diseases Unit of our hospital were prospectively followed. For the purpose of the study, we chose January 1997 as the starting date of the study because HAART was not widely available in our hospital until that time. The Institutional Review Board at Hospital Clínic approved this study. Patients initiating or changing antiretroviral therapy were visited at least 1 month after the introduction of the HAART regimen and every 3 6 months thereafter. Clinical and laboratory data for patients were recorded at each visit. This cohort has been previously described [19 21] and represents one of the largest cohorts of HIV-infected adults from a single institution in Spain. HAART was defined as at least triple therapy including two nucleoside reverse transcriptase inhibitors (NRTIs) plus at least one protease inhibitor (PI) or one nonnucleoside reverse transcriptase inhibitor (NNRTI) or a third NRTI. Criteria for initiation or maintenance of HAART were based on the updated recommendations existing at the time of the study. Patients for whom HAART was not recommended and those for whom it was recommended but not taken up were not included in this study. Antiretroviral therapy could be modified at the discretion of the treating physician, and patients remained in the study as long as they remained on HAART. For the purpose of the study, patients who discontinued antiretroviral therapy were retained in the study if the time without HAART was less than 3 months. Reasons for censoring were death, loss to follow-up, discontinuation of HAART longer than 3 months, or use of antiretroviral therapy not included in the definition of HAART, whichever came first. Deaths were identified either directly from physician reports for patients who died during hospital admission or indirectly through inquiries to relatives or friends for patients who missed their last scheduled visit. Systematic inquiries to the National Register Office were also made to confirm death in those patients with missing visits. Special efforts were made to ultimately ascertain the cause of death in each patient from available sources. When more than one cause of death was reported, only the primary cause of death was considered. The death was considered related to AIDS if the primary cause of death was an AIDS-defining condition. Cause of death was classified as unknown if there was no death certificate available or if the cause of death was not provided. The most recent laboratory values of CD4 cell counts and plasma HIV RNA prior to death were identified for each individual and were included in the analyses as death-related if measured within the 6 months prior to death. Early death was defined when occurring in the first 6 months after initiation of HAART because the risk of AIDS-defining events potentially leading to death in patients with advanced HIV infection is higher during this period [22]. Estimations of the annual incidence and causes of death in the population of Catalonia per calendar year in the study period were obtained from the Institut d Estadística de Catalunya [23], in which deceased persons are grouped by age. The group in the general population aged years at death was chosen for comparison with HIVinfected patients because it matched the median age and range of the HIV-infected patients who died in our cohort. Specific data for smaller age groups within the age group years were not available for analysis. Annual
3 Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy 253 mortality rates in the HIV-infected cohort and in the general population were calculated as the number of deaths per 100 person-years by year. Univariate analyses were performed using the w 2 test, Fisher s exact test, Student s t-test, the Wilcoxon test or the Kruskal Wallis test, as appropriate. Adjusted odds ratios for death at different time-points were compared using the w 2 test for linear trend. Multivariate analyses through logistic regression models were used to assess the factors associated with HIV-related death among patients who died. Variables examined included age, gender, route of HIV transmission, CD4 cell count and plasma HIV-1 RNA at the initiation of HAART, active use of illicit drugs, hepatitis C or B virus infection (defined by positive serological tests), non- HAART antiretroviral therapy prior to the use of HAART, and duration of exposure to HAART. Time-to-event analysis was used to assess the incidence of the most common causes of death in HIV-infected patients. Statistical analysis was performed using STATA software (release 7.0; StataCorp, College Station, TX). Statistical significance was determined using two-tailed tests, with Po0.05 considered to be significant. Results Characteristics of the HIV-infected patients who died Of the 4471 patients on HAART followed in the study period, 235 patients (5%) died. The patients who died were more commonly men (n 5 183, 78% vs. n , 72%; P , Fisher s exact test) and older at the initiation of HAART [median age (interquartile range) 40 (34, 47) vs. 34 (30, 40) years; P ; Wilcoxon rank sum test] than those remaining alive (n ). Persons who acquired HIV infection through injecting drug use were overrepresented in the population of patients who died (53% vs. 44%; P ; Fisher s exact test), but persons who acquired HIV infection through homosexual male contact (31% vs. 32%; P ; Fisher s exact test), heterosexual contact (17% vs. 19%; P ; Fisher s exact test) or haemophilia (2% vs. 5%; P ; Fisher s exact test) were not. As expected, baseline CD4 cell counts in patients who died were lower [median (interquartile range) 114 (32, 227) cells/ml, n vs. 339 ( ) cells/ml, n ; Po0.001; Wilcoxon rank sum test] and baseline plasma HIV RNA levels were higher [median (interquartile range) 5.4 (4.2, 6.4) log 10 copies/ml, n vs. 4.9 (3.8, 5.6) log 10 copies/ml, n ; Po0.001, Wilcoxon rank sum test] than the respective baseline values obtained for patients who remained alive. Incidence of mortality The number (percentage of all HIV-infected patients receiving care in the hospital) of HIV-infected patients on HAART in the cohort per year was 1127 (83%) in 1997, 1674 (92%) in 1998, 1946 (95%) in 1999, 2037 (95%) in 2000, 2112 (93%) in 2001, 2094 (88%) in 2002, 2028 (85%) in 2003, and 2053 (84%) in The number (percentage of all patients on HAART) of HIV-infected patients on HAART who died each year was 51 (5%) in 1997, 45 (3%) in 1998, 31 (2%) in 1999, 18 (1%) in 2000, 18 (1%) in 2001, 21 (1%) in 2002, 24 (1%) in 2003, and 27 (1%) in The population of Catalonia aged years increased progressively in the years of the study, from persons in 1997 to persons in The number of deaths in this sector of the population tended to decrease with time, from a maximum of 9952 deaths in 1999 to a minimum of 9096 in The annual incidence of mortality in the HIV-infected cohort as compared with that in the general population aged years in Catalonia is shown in Fig. 1. There was a significant decrease over this period for HIV-infected patients (Po0.001; w 2 test for trend), but there were no significant changes for the general population (P ; w 2 test for trend). The effect of time was not linear for the HIV-infected cohort (Fig. 1). Nevertheless, the slight increase after 2000 was not found to be statistically significant in a test for nonlinear trend. Causes of mortality The general causes of mortality in the HIV-infected cohort in decreasing order were AIDS-defining events (n 5 95; 40%), late-stage liver disease (n 5 53; 23%), non-aids- Mortality per 100 person-years Calendar year Fig. 1 Annual incidence of mortality in the HIV-infected cohort as compared with the general population aged years in Catalonia. There were significant changes over this period for HIVinfected patients (Po0.001; w 2 test for trend), but not for the general population (P ; w 2 test for trend).
4 254 E Martínez et al. Table 1 Major and specific causes of mortality (n 5 235) in the cohort of HIV-infected patients receiving highly active antiretroviral therapy (HAART) Cause of death AIDS-defining events 95 (40%) Non-Hodgkin lymphoma 22 Cytomegalovirus disease 20 Tuberculosis 19 Pneumocystis jiroveci pneumonia 15 Mycobacterium avium intracellulare disseminated infection 8 Progressive multifocal leucoencephalopathy 6 Toxoplasmic encephalitis 2 Disseminated cryptococcosis 2 Kaposi sarcoma 1 Late-stage liver disease 53 (23%) Hepatitis C virus-related 42 Hepatitis B virus-related 6 Hepatitis C and B virus-related 3 Nonviral cirrhosis 2 Non-AIDS-defining, nonhepatitis infections 33 (14%) Pneumonia 16 Sepsis 13 Abdominal infections 3 Pulmonary aspergilosis 1 Non-AIDS-defining, nonhepatitis-related neoplasia 25 (11%) Lung 10 Colon 8 Pancreas 2 Unknown origin 2 Prostate 1 Breast 1 Thyroid 1 Cardiovascular disease 14 (6%) Myocardial infarction 12 Cerebrovascular disease 2 Drug overdose 6 (3%) Accidental/traumatic events 2 (1%) Car crash 1 Weapon injury 1 Suicide 3 (1%) Unknown 4 (2%) n defining, nonhepatitis infections (n 5 33; 14%), non-aidsdefining, nonhepatitis-related neoplasia (n 5 25; 11%), cardiovascular disease (n 5 14; 6%), drug overdose (n 5 6; 3%), unknown (n 5 4; 2%), suicide (n 5 3; 1%), and accidental/traumatic events (n 5 2; 1%) (Table 1). Seventy-five patients (32%) had a viral load o200 copies/ ml at the time of death. Compared with patients dying with 200 copies/ml (n 5 102), patients dying with o200 copies/ml (n 5 75) died more commonly of late-stage liver disease (n 5 33, 44% vs. n 5 17, 17%), non-aids-defining, nonhepatitis-related neoplasia (n 5 14, 19% vs. n 5 10, 10%), and cardiovascular disease (n 5 8, 11% vs. n 5 5, 5%), and less commonly of AIDS-defining events (n 5 14, 19% vs. n 5 35, 34%), non-aids-defining, nonhepatitis infections (n 5 4, 5% vs. n 5 26, 25%), and drug overdose (n 5 1, 1% vs. n 5 2, 2%) (Po0.001; Fisher s exact test). The proportion of deaths attributable to AIDS-defining events significantly decreased over time, from 84% in 1997 to 7% in 2004 (Po0.001; w 2 test for trend) (Table 2). Among deaths attributable to non-aids-defining events, the proportion from late-stage liver disease (Po0.001; w 2 test for trend) and non-aids-defining infections (P ; w 2 test for trend) significantly increased with time (Table 2), and these causes were responsible for the slight increase in the incidence of mortality after We were unable to find any significant trend with time regarding other causes of death among HIV-infected patients. In the general population of Catalonia of a similar age, the annual rates of cardiovascular diseases, accidental/ traumatic events, and suicide as causes of death tended to increase, whereas neoplasia in general, liver diseases, and infections in general tended to decrease during the study period (data not shown). Table 2 Distribution of the number of patients dying per year according to major causes of mortality n AIDS-defining events (n 5 95) 43 (84) 20 (44) 13 (42) 6 (33) 4 (22) 5 (24) 2 (8) 2 (7) Late-stage liver disease (n 5 53) 4 (8) 7 (16) 3 (10) 6 (33) 5 (28) 7 (33) 10 (42) 11 (41) Non-AIDS-defining, nonhepatitis 1 (2) 2 (4) 7 (23) 2 (11) 1 (6) 4 (19) 8 (33) 8 (30) infections (n 5 33) Non-AIDS-defining, nonhepatitis-related 2 (4) 7 (16) 7 (23) 1 (6) 5 (28) 1 (5) 0 2 (7) neoplasia (n 5 25) Cardiovascular disease (n 5 14) 0 3 (7) 0 3 (17) 2 (11) 2 (10) 2 (8) 2 (7) Drug overdose (n 5 6) 0 3 (7) 1 (3) 0 1 (6) 1 (5) 0 0 Accidental/traumatic events (n 5 2) 0 1 (2) (5) 0 0 Unknown (n 5 4) (8) 2 (7) Total (n 5 235) 51 (100) 45 (100) 31 (100) 18 (100) 18 (100) 21 (100) 24 (100) 27 (100) Trends over time were significant for AIDS-defining events (Po0.001), late-stage liver disease (Po0.001) and non-aids-defining, nonhepatitis infections (P ), but not for other causes of death (P40.05) (w 2 test for linear trend).
5 Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy 255 Table 3 Deaths stratified by cause in the cohort of HIV-infected patients receiving highly active antiretroviral therapy (HAART) and in the general population of Catalonia aged years in the period of the study n (%) Cause of death HIV-infected patients receiving HAART (n 5 235) General population Catalonia aged years (n ) 0.25 Infections with viruses, parasites, 53 (23) 467 (0.6) fungi, and nontuberculosis mycobacteria Bacterial infections 32 (14) 354 (0.5) Tuberculosis 19 (8) 143 (0.2) Lymphoma 22 (9)* 1436 (2) Neoplasia other than lymphoma 26 (11) (44) Cardiovascular diseases 14 (6) (19) Liver diseases 53 (23) 1507 (2) Suicide 3 (1) 2216 (3) Accidental/traumatic events 2 (1) 9798 (13) For comparison purposes, the causes of death have been grouped according to the classification system used in the general population of Catalonia by the Institut d Estadística de Catalunya [6]. There were additional HIVinfected patients who died from a drug overdose (n 5 6) and unknown causes (n 5 4) who are not included in the table because we were unable to assess the rates of mortality from these causes in the general population. There were other causes of death in the general population that are not listed here because they could not be compared with similar causes in the cohort of HIV-infected patients (e.g. neurological and renal causes). *All cases of lymphoma leading to death in HIV-infected patients were non-hodgkin lymphoma. Infections in general [85 HIV-infected patients (36%) vs. 821 individuals in the general population (1%); 33 times higher in HIV-infected patients] and liver diseases [53 HIV-infected patients (23%) vs individuals in the general population persons (2%); 11 times higher in HIV-infected patients] as causes of death were clearly overrepresented among HIV-infected patients, whereas neoplasia other than lymphoma [26 HIV-infected patients (11%) vs individuals in the general population (44%); 4 times lower in HIV-infected patients], cardiovascular diseases [14 HIV-infected patients (6%) vs individuals in the general population (19%); 3 times lower in HIV-infected patients], and accidental/traumatic events [two HIV-infected patients (1%) vs individuals in the general population (13%); 15 times lower in HIV-infected patients] were underrepresented compared with the general population of Catalonia of a similar age (Table 3). Non- Hodgkin lymphoma was the most common neoplasia leading to death in the cohort of HIV-infected patients (n 5 22; 46% of the deaths attributable to neoplasia), and this cause was overrepresented compared with the general population [22 HIV-infected patients (9%) vs individuals in the general population (2%); 5 times higher in HIV-infected patients] Months after the initiation of HAART AIDS events Non-AIDS neoplasia Liver disease Cardiovascular disease Fig. 2 Kaplan Meier survival estimates by cause of death for the four most common causes of death: AIDS-defining events, non-aids neoplasia, liver disease and cardiovascular disease. There were significant differences in the overall comparison among the four causes (Po0.001; generalized log-rank test). The comparisons between AIDS-defining events and non-aids neoplasia (Po0.001; log-rank test) and between AIDS-defining events and cardiovascular disease (P ; log-rank test), and the comparisons between liver disease and non-aids neoplasia (P ; log-rank test) and between liver disease and cardiovascular disease (P ; log-rank test) were also significant. AIDS-related vs. non-aids-related deaths Ninety-five patients (40%) died as a result of AIDSdefining events. Patients dying of AIDS-defining events were younger (median, interquartile range, n: 38, years, 95 vs. 42, years, 140; P ; Wilcoxon rank sum test), were more commonly men (n, %: 81, 85% vs. 102, 73%; P ; Fisher s exact test), and had more commonly acquired HIV infection through the parenteral (rather than sexual) route (n, %: 50, 53% vs. 45, 47%; P ; Fisher s exact test) than patients dying of non- AIDS-defining events. CD4 counts (cells/ml) in patients dying of AIDS-defining events at the initiation of HAART (median, interquartile range, n: 123, , 95 vs. 167, , 134; P ; Wilcoxon rank sum test) and at the time of death (median, interquartile range, n: 63, , 95 vs. 154, , 135; Po0.0001; Wilcoxon rank sum test) were significantly lower than in patients dying as a result of non-aids-defining events. Plasma HIV RNA (log copies/ml) in patients dying of AIDS-defining events at the initiation of HAART (median, interquartile range, n: 5.5, , 37 vs. 5.2, , 95; P ; Wilcoxon rank sum test) and at the time of death (median, interquartile range, n: 4.9, , 49 vs. 2.9, , 128; P ; Wilcoxon rank sum test) was significantly higher than in patients dying of non-aids-defining events. Multivariate analysis identified two independent risk factors for dying of an AIDS-defining event in
6 256 E Martínez et al. HIV-infected patients receiving HAART: a CD4 cell count lower than 200 cells/ml at the initiation of HAART (adjusted odds ratio 5.4; 95% confidence interval ; P ) and an increasing plasma viral load at the initiation of HAART (per unit log copies/ml) (adjusted odds ratio 4.5; 95% confidence interval ; P ). Time to death after the initiation of HAART in HIVinfected patients who died Ninety patients (38%) died in the first 6 months after the initiation of HAART. AIDS-defining events (n 5 60; 63%), drug overdose (n 5 4; 67%), and suicide (n 5 2; 67%) were more concentrated in the first 6 months on HAART than other causes of death: non-aids-defining infections (n 5 9; 27%), non-aids-defining neoplasia (n 5 5; 20%), late-stage liver disease (n 5 8; 15%), cardiovascular disease (n 5 2; 14%), and accidental/traumatic events (n 5 0; 0%) (Po0.001; Fisher s exact test). There were no significant differences in the annual distribution of causes of early death per year (data not shown). The Kaplan Meier survival estimates for the four major causes of death in this cohort (AIDS-defining events, non-aids-defining neoplasia, late-stage liver disease and cardiovascular disease) showed significant differences among them (Fig. 2) (Po0.001; generalized log-rank test). Patients who died of an AIDS-defining event did so earlier than patients who died of non-aids-defining neoplasia (Po0.001; log-rank test) and cardiovascular disease (P ; log-rank test). Patients who died of end-stage liver disease also died earlier than patients who died of non- AIDS-defining neoplasia (P ; log-rank test) and cardiovascular disease (P ; log-rank test) (Fig. 2). Discussion Among HIV-infected patients receiving HAART, we have confirmed that patients who acquired HIV infection through injecting drug use, and those who had lower CD4 cell counts and higher plasma viral loads at baseline had a higher risk of death. A higher risk of death in former or current injecting drug users has also been reported in several previous studies, and factors such as drug overdose, chronic viral hepatitis and end-stage liver disease, and a higher risk of bacterial infections and suicide might at least partly explain the higher risk of mortality in this population [12,13,24 27]. Data from very large cohort studies have also shown that both baseline [6] and current [8] low CD4 cell counts and baseline [6] high plasma viral load are associated with a higher risk of death. It is surprising that the higher risk of death associated with advanced immune suppression [8] and uncontrolled viral suppression in therapy interruption studies [9] seems to be a result not only of AIDS-defining events but also of non-hiv-related causes. There was a decreasing incidence of mortality in our cohort from 1997 until 2000, with a slightly increasing plateau from 2000 until However, even in the latter period, the incidence of mortality in HIV-infected patients was approximately five times higher than that in the agematched general population. These data are in accordance with those recently reported by others [18,24,28,29] and emphasize the need for additional measures to decrease further the incidence of mortality in HIV-infected patients despite the availability of HAART. Although AIDS-related events have been the most common cause of death during the study period, there has been a significant decrease over time, whereas liver diseases and non-aids-defining infections have been significantly increasing over time. Among HIV-infected patients who died, those with lower CD4 cell counts and higher plasma viral loads were more likely to die of an AIDS-defining event than of other causes. Patients dying of an AIDS-event also died earlier than patients dying of other non-hiv-related causes such as neoplasia or cardiovascular disease. This fact may reflect the lag in the immunological and clinical benefit in highly immunesuppressed patients despite the availability of effective HAART. Almost one-third of the patients died with optimal suppression of plasma viral replication, and the causes of death in these patients were more commonly noninfectious diseases. Several studies have highlighted the increasing importance of liver-related disease as a cause of death in HIV-infected patients [14,18]. Although a specific analysis of the EuroSIDA cohort found a decreasing rate of death from liver-related disease, explained in part by increases in CD4 cell count after starting antiretroviral therapy, there was an increase in deaths from liver-related disease over time after adjustment for antiretroviral-induced CD4 cell increases [13]. Patients coinfected with hepatitis B or C virus are also well known to have an increased death rate from liver-related disease [30]. Non-AIDS-defining infections have been shown to decrease with HAART in some studies [18], but some others have shown the opposite effect [14]. In general, the causes of death in HIV-infected patients receiving HAART have been understudied, and some experts have pointed out the need to define and standardize causes of death in these patients more effectively [12]. When comparing the rates of death from specific causes, we were able to detect an excess of mortality in HIVinfected patients treated with HAART attributable to infections in general and to liver diseases. The impact of infectious causes may be attributable at least in part to
7 Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy 257 AIDS-defining events, which were among the most common causes of death at the beginning of the study. However, other AIDS-defining infections that are not exclusive of HIV infection, such as tuberculosis, and bacterial infections were overrepresented in HIV-infected patients compared with the general population. The reasons for this excess mortality from non-aids-defining infections are not clear. Despite the controversy on whether there has been a decrease or an increase in deaths from liver-related diseases in HIV-infected patients on HAART over time [13], our data suggest that liver-related deaths are clearly overrepresented in these patients compared with the age-matched general population. The incidence of systemic non-hodgkin lymphoma in HIV-infected patients has not clearly decreased as a result of the use of HAART [31], and the survival rate in HIV-infected patients is still lower than that in non-hiv-infected persons, despite the fact that survival has improved with effective HAART [32]. Our study has several limitations. We compared the causes of death in HIV-infected individuals with those in the general population, but the general population is not an epidemiologically relevant reference group. HIV-infected individuals are different from the general population in various respects, such as in having more comorbidities or more behavioural and psychological impairments, and the conceptual approach of comparison with the general population may be of arguable validity, particularly in the light of the limited covariates available in the general population. Although we assessed the causes of death in HIV-infected persons using a simple algorithm, it is possible that the methods used to assess the causes of death in the general population were different. The available data on the follow-up of HIV-infected patients remaining alive were too limited to enable calculation of standardized mortality ratios in the HIV-infected cohort. Finally, we were not able to take into account competing events in investigating the incidence of the different causes of death in HIV-infected individuals. Despite these limitations, we believe that our study offers a potentially valuable insight into the trends of mortality in HIVinfected persons receiving HAART. In summary, mortality in HIV-infected patients receiving HAART has decreased over time but is still higher than that in the general population of a similar age. While AIDSdefining events have been steadily decreasing as a cause of death, there has been an increase in deaths from non-aidsrelated infections and liver-related diseases. These increasingly common causes of death, together with non-hodgkin lymphoma, are clearly overrepresented in HIV-infected patients receiving HAART compared with the age-matched general population, and they represent specific targets for efforts to decrease further the mortality in this population. Acknowledgements This study was supported in part by a grant from the Red Temática Cooperativa de Grupos de Investigación en Sida del Fondo de Investigación Sanitaria (FIS), and grant ISCIII-RETIC RD06/006 from the Instituto de Salud Carlos III, Madrid (Spain). Dr. E. Martinez and Dr. J. M. Miró were recipients of a Research Grant from the Institut d Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and the Conselleria de Salut de la Generalitat de Catalunya, Barcelona (Spain). References 1 Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss Cohort Study. Br Med J 1997; 315: Pallella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: Sterne JAC, Hernán MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: Schneider MF, Gange SJ, Williams CM et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: AIDS 2005; 19: Weber R, Friis-Mller N, Sabin C et al HIV and non-hiv-related deaths and their relationship to immunodeficiency: The D.A.D. Study. XIIth Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 595]. 9 El-Sadr W, Neaton J. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART Study. XIIIth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 106LB]. 10 Egger M, May M, Chêne G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:
8 258 E Martínez et al. 11 Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: Mocroft A, Gatell J, Reiss P et al. Causes of death in HIV infection: the key determinant to define the clinical response to anti-hiv therapy. AIDS 2004; 18: Mocroft A, Soriano V, Rockstroh J et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in the causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco J Infect Dis 2002; 186: Wang C, Vlahov D, Galai N et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190: Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to HIV Med 2005; 6: Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: Crum NF, Riffenburgh RH, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: Pérez-Cuevas B. Influencia del Tratamiento Antirretrovírico de Gran Actividad en la Incidencia de las Infecciones Oportunistas y Neoplasias Asociadas a la Infección por VIH-1 y en la Mortalidad. TDX /TOL33.pdf Martinez E, Mocroft A, Garcia-Viejo MA et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: Garcia F, de Lazzari E, Plana M et al. Long-term CD4 1 T-cell response to highly active antiretroviral therapy according to baseline CD4 1 T-cell count. J Acquir Immune Defic Syndr 2004; 36: Michelet C, Arvieux C, Francois C et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 2006; 12: Iustitut d Estadística de Catalunya. Estudis de la població van Sighem A, Danner S, Ghani AC et al. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-hiv-infected individuals. J Acquir Immune Defic Syndr 2005; 40: Pérez-Hoyos S, Ferreros I, del Amo J et al. Survival and progression to AIDS in a seroconverter cohort in the posthighly active antiretroviral therapy era: effectiveness goes on. AIDS 2006; 20: Sabin C. on behalf of the Antiretroviral Therapy Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19: Lloyd-Smith E, Brodkin E, Wood E et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006; 20: Jaggy C, von Overbeck J, Ledergerber B et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: Keiser O, Taffé P, Zwahlen M et al. All cause mortality in the Swiss HIV cohort study from 1999 to 2001 in comparison with the Swiss population. AIDS 2004; 18: Rockstroh J, Konopnicki D, Mocroft A et al. Hepatitis B. and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART. XIth Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 799]. 31 Kirk O, Pedersen C, Cozzi-Lepri A et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: Gerard L, Galicier L, Maillard A et al. Systemic non-hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002; 30:
To interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationThe importance of cohort collaborations for guiding clinical management of individuals with HIV infection
The importance of cohort collaborations for guiding clinical management of individuals with HIV infection Caroline Sabin Professor of Medical Statistics and Epidemiology Royal Free and University College
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationSupervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles
I Congreso de GESIDA Madrid, 21-24 de Octubre del 2009. Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles José M. Miró, 1 Miguel Montejo,
More informationMethods. Linking three datasets BRIEF COMMUNICATION
BRIEF COMMUNICATION Changes in Causes of Death and Associated Conditions Among Persons with HIV/AIDS After the Introduction of Highly Active Antiretroviral Therapy in Taiwan Tsung-Hsueh Lu, Hong-Jen Chang,
More informationDefinitions of antiretroviral treatment failure for measuring quality outcomes
DOI: 10.1111/j.1468-1293.2009.00808.x r 2010 British HIV Association HIV Medicine (2010), 11, 427 431 ORIGINAL RESEARCH Definitions of antiretroviral treatment failure for measuring quality outcomes A
More informationMortality rates among injection drug users (IDUs) have been historically high and are still significantly higher
HIV/AIDS MAJOR ARTICLE Survival of HIV-Infected Injection Drug Users (IDUs) in the Highly Active Antiretroviral Therapy Era, Relative to Sex- and Age-Specific Survival of HIV-Uninfected IDUs Roberto Muga,
More informationHIV Update For the Internist
HIV Update For the Internist Disclosures I declare that I have received no incentives, financial or otherwise, from pharmaceutical or biomedical companies relevant to the content of this talk. As an Infectious
More informationORIGINAL INVESTIGATION. CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study ORIGINAL INVESTIGATION Gilbert R. Kaufmann, MD; Luc
More informationChanges over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks
International Epidemiological Association 2002 Printed in Great Britain International Journal of Epidemiology 2002;31:951 958 Changes over calendar time in the risk of specific first AIDS-defining events
More informationMortality and causes of death in HIV positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital
ORIGINAL ARTICLE Mortality and causes of death in HIV positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital Mogiyana Olga Mzileni 1, Benjamin Longo Mbenza
More informationAntiretroviral Therapy Cohort Collaboration
Antiretroviral Therapy Cohort Collaboration http://www.bristol.ac.uk/art-cc/research/presentations/ 2015 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 2015 Margaret
More informationMortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013
John F. White III, MD, MBA, FLMI VP and Medical Director American National Insurance Company 1 Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 2 1 3 My Opinions
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationOCCURRENCE OF PNEUMOCYSTIS PNEUMONIA IN HIV-INFECTED PATIENTS AND THE INTERFERENCE OF THE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
Received: August 24, 2007 Accepted: December 6, 2007 Abstract published online: December 17, 2007 Full paper published online: March 8, 2008 J. Venom. Anim. Toxins incl. Trop. Dis. V.14, n.1, p.152-160,
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationFor any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,
Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01367.x Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated
More informationMortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral Therapy
HIV/AIDS MAJOR ARTICLE Mortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral Therapy Rakhi Kohli, 1,a Yungtai Lo, 2 Andrea A. Howard, 1,2 Donna
More informationSan Francisco AIDS Cases Reported Through December 31, 1998
San Francisco AIDS Cases Reported Through December 31, 1998 San Francisco Department of Public Health HIV Seroepidemiology and Surveillance Section AIDS Surveillance Unit Contents Page Commentary: Trends
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationDepartment of Clinical Epidemiology, Institute of Infectious Disease and Epidemiology, Tan Tock Seng Hospital, Singapore 2
Original Article 563 Causes of Death and Factors Associated with Early Death Among Human Immunodeficiency Virus (HIV)-Infected Persons in Singapore: Pre-Highly Active Antiretroviral Therapy (HAART) and
More informationIncomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment
MAJOR ARTICLE HIV/AIDS Incomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment Colleen F. Kelley, 1,a Christina M. R. Kitchen, 2,a Peter
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationMortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord
Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus Infected Cohort
More information(See the editorial commentary by Sasson et al. on pages 373 5)
MAJOR ARTICLE HIV/AIDS Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to!500 Cells/mL in HIV Type 1 Infected Individuals Receiving Potent Antiretroviral Therapy Gilbert R.
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRelationship between Adherence Level, Type of the Antiretroviral Regimen, and Plasma HIV Type 1 RNA Viral Load: A Prospective Cohort Study
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 24, Number 10, 2008 Mary Ann Liebert, Inc. DOI: 10.1089/aid.2008.0141 Relationship between Adherence Level, Type of the Antiretroviral Regimen, and Plasma HIV
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationHIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS
HIV/AIDS CLINICAL CARE QUALITY MANAGEMENT CHART REVIEW CHARACTERISTICS OF PATIENTS WITH LOW CD4 COUNTS IN 2008 AND FACTORS ASSOCIATED WITH IMPROVED IMMUNOLOGIC STATUS FROM 2004 THROUGH 2008 For the Boston
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationMORTALITY TRENDS OF HIV-INFECTED PATIENTS AFTER THE INTRODUCTION
MORTALITY TRENDS OF HIV-INFECTED PATIENTS AFTER THE INTRODUCTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: ANALYSIS OF A COHORT OF 3,322 HIV-INFECTED PERSONS Introduction: The implementation of highly active
More informationCozzi-Lepri, A.
https://helda.helsinki.fi Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens Cozzi-Lepri,
More information[RH], ; 95% ; P
1086 Human Immunodeficiency Virus Rebound after Suppression to!400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression
More informationAntiretroviral therapy (ART) has led to a substantial
EPIDEMIOLOGY AND SOCIAL SCIENCE Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients The Swiss HIV Cohort Study Tracy R. Glass, MSc,* Sabina De Geest, PhD, Rainer
More informationThe Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients
American Journal of Infectious Diseases 4 (2): 147-151, 2008 ISSN 1553-6203 2008 Science Publications The Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationUniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study
Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study Cornelia Junghans a, Nicola Low a, Philip Chan a, Anne Witschi b,c,
More informationDiscontinuation of Secondary Prophylaxis against Disseminated Mycobacterium avium Complex Infection and Toxoplasmic Encephalitis
HIV/AIDS MAJOR ARTICLE Discontinuation of Secondary Prophylaxis against Disseminated Mycobacterium avium Complex Infection and Toxoplasmic Encephalitis Valérie Zeller, 1 Chantal Truffot, 2 Rachid Agher,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationReduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
ACTA BIOMED 2007; 78: 36-40 Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
More informationCancer risk and prevention in persons living with HIV/AIDS (PLWHA) Robert Dubrow, MD, PhD Professor of Epidemiology Yale School of Public Health
Cancer risk and prevention in persons living with HIV/AIDS (PLWHA) Robert Dubrow, MD, PhD Professor of Epidemiology Yale School of Public Health Main collaborators Lesley Park Janet Tate Amy Justice Michael
More informationORIGINAL INVESTIGATION. Cirrhosis and Hepatocellular Carcinoma in HIV-Infected Veterans With and Without the Hepatitis C Virus
ORIGINAL INVESTIGATION Cirrhosis and Hepatocellular Carcinoma in HIV-Infected Veterans With and Without the Hepatitis C Virus A Cohort Study, 1992-2001 Thomas P. Giordano, MD, MPH; Jennifer R. Kramer,
More informationThe incidence of lymphoma in the UK haemophilia population between 1978 and 1999
The incidence of lymphoma in the UK haemophilia population between 1978 and 1999 Jonathan T. Wilde a, Christine A. Lee b, Sarah C. Darby c, Sau Wan Kan c, Paul Giangrande d, Andrew N. Phillips e, Mark
More informationIschemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection
HIV/AIDS MAJOR ARTICLE Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection Max H. David, 1,3 Richard Hornung, 2 and Carl J. Fichtenbaum 1 1 Department of Medicine, Division
More informationDr Claire Townsend on behalf of EPPICC. Presented at the 2 nd International Workshop on HIV Pediatrics July 2010, Vienna Austria
Response to early antiretroviral treatment in HIV-infected infants: the experience of the European Pregnancy & Paediatric HIV Cohort Collaboration (EPPICC) Dr Claire Townsend on behalf of EPPICC Background
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationAssociation of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction
CLINICAL SCIENCE Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction Virginia A. Triant, MD, MPH,* James B. Meigs, MD, MPH, and Steven K. Grinspoon, MD Objective: To investigate
More informationPrimary Care for Persons Living with HIV
Primary Care for Persons Living with HIV Brian Montague, DO MS MPH Assistant Professor of Medicine Division of Infectious Diseases Warren Alpert School of Medicine Brown University Outline What constitutes
More informationGESIDA 2018 ANTIRETROVIRAL TREATMENT MAINTENANCE STRATEGIES AND BLOOD TELOMERE LENGTH CHANGE
ANTIRETROVIRAL TREATMENT MAINTENANCE STRATEGIES AND BLOOD TELOMERE LENGTH CHANGE Rocío Montejano 1, Natalia Stella-Ascariz 1, Susana Monge 1, Jose I Bernardino 1, Ignacio Perez-Valero 1, Marisa Montes
More informationOUTCOMES OF HIV-INFECTED THERAPY INCLUDING
UNIVERSIDADE FEDERAL DA BAHIA FACULDADE DE MEDICINA DA BAHIA PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA E SAÚDE OUTCOMES OF HIV-INFECTED PATIENTS RECEIVING RESCUE THERAPY INCLUDING RALTEGRAVIR Patino-Escarcina
More informationTools to Monitor HIV Infection in 2013 and Beyond.
Tools to Monitor HIV Infection in 2013 and Beyond. Federico García, fegarcia@ugr.es Servicio de Microbiología Univ. Hospital San Cecilio Granada, Spain Outline Address clinical questions: Ultra sensitive
More informationFactors Associated with Limitations in Daily Activity Among Older HIV+ Adults
Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults KM Erlandson, K Wu, R Kalayjian, S Koletar, B Taiwo, FJ Palella Jr, K Tassiopoulos and the A5322 Team Background Growing burden
More informationDecreasing rates of Kaposi's sarcoma and non-hodgkin's lymphoma in the era of potent combination antiretroviral
CONCISE COMMUNICATION Decreasing rates of Kaposi's sarcoma and non-hodgkin's lymphoma in the era of potent combination antiretroviral therapy Andrew E. Grulich, Yueming Li, Ann M. McDonald, Patricia K.
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationTrends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit
SUPPLEMENT ARTICLE Trends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit Roberto Muga, Arantza Sanvisens, José Manuel Egea, Jordi Tor, and Celestino Rey-Joly Department
More informationJMSCR Vol 3 Issue 10 Page October 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x DOI: http://dx.doi.org/10.18535/jmscr/v3i10.20 Drugs Related Changes of Haemoglobin and CD4 Counts in HIV-Infected Patients on Antiretroviral
More informationMarked and sustained reductions in AIDS-related death and
PEN.012.1092 CLINICAL SCIENCE Mortality in the Highly Active Antiretroviral Therapy Era Changing Causes of Death and Disease in the HIV Outpatient Study Frank J. Palella, Jr., MD,* Rose K. Baker, MA,Þ
More informationLack of association between use of efavirenzand death from suicide: the D:A:D Study
Lack of association between use of efavirenzand death from suicide: the D:A:D Study Colette Smith, Lene Ryom, Antonellad ArminioMonforte, Peter Reiss, Amanda Mocroft, Wafaa el Sadr, Rainer Weber, Mathew
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationSituación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona
Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona Mortality per 1 patient-years HIV infection has changed from a fatal disease into a chronic condition This means long-term
More informationHighly Active Antiretroviral Therapy and Survival in HIV-Infected Injection Drug Users
ORIGINAL CONTRIBUTION Highly Active Antiretroviral Therapy and Survival in HIV-Infected Injection Drug Users Evan Wood, MD, PhD Robert S. Hogg, PhD Viviane Dias Lima, PhD Thomas Kerr, PhD Benita Yip, BSc
More informationINTEGRATING HIV INTO PRIMARY CARE
INTEGRATING HIV INTO PRIMARY CARE ADELERO ADEBAJO, MD, MPH, AAHIVS, FACP NO DISCLOSURE 1.2 million people in the United States are living with HIV infection and 1 in 5 are unaware of their infection.
More informationIMMunoCoMPEtEnCE. PatIEnts and MEtHods
March 28, 2011 Eu Ro PE an JouR nal of MEd I Cal RE search 101 Eur J Med Res (2011) 16: 101-107 I. Holzapfel Publishers 2011 CanCER RIsk In HIV-InfECtEd IndIVIduals on HaaRt Is largely attributed to oncogenic
More informationClinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?
Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationAntiviral Therapy 13:77 85
Original article Antiviral Therapy 13:77 85 Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients Tracy
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Risk of Progression to AIDS and Death in Women Infected With HIV-1 Initiating Highly Active Antiretroviral Treatment at Different Stages of Disease Kathryn Anastos, MD; Yolanda Barrón,
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationJournal of Antimicrobial Chemotherapy Advance Access published December 30, 2005
Journal of Antimicrobial Chemotherapy Advance Access published December 30, 2005 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dki472 Safety and factors predicting the duration of first and second
More informationLong-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study Jonathan A C Sterne, Miguel A Hernán, Bruno Ledergerber, Kate Tilling, Rainer Weber, Pedram
More informationIntegrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection
Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Juan Ambrosioni, David Nicolás, Christian Manzardo, Fernando Agüero, José Luis Blanco, Maria del Mar
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationTreatment outcomes in HIV/tuberculosis co-infected patients with CD4 cell counts < 200 cells/mm 3 and 200 cells/mm 3
Original Article Vol. 29 No. 2 Treatment outcomes in HIV/TB co-infection:- Rattanamaneekorn S & Sungkanuparph S. 5 Treatment outcomes in HIV/tuberculosis co-infected patients with CD4 cell counts < 200
More informationThe Struggle with Infectious Disease. Lecture 6
The Struggle with Infectious Disease Lecture 6 HIV/AIDS It is generally believed that: Human Immunodeficiency Virus --------- causes ------------- Acquired Immunodeficiency Syndrome History of HIV HIV
More informationAIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy JAMA. 1999;282:
ORIGINAL CONTRIBUTION AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy The Swiss HIV Cohort Study Bruno Ledergerber, PhD Matthias Egger, MD Véronique Erard,
More informationCANCER FOLLOWING COMBINATION ANTIRETROVIRAL THERAPY INITIATION: INCIDENCE PATTERNS AND EFFECTS OF ANTIRETROVIRAL RESPONSE. Elizabeth L.
CANCER FOLLOWING COMBINATION ANTIRETROVIRAL THERAPY INITIATION: INCIDENCE PATTERNS AND EFFECTS OF ANTIRETROVIRAL RESPONSE Elizabeth L. Yanik, ScM A dissertation submitted to the faculty of the University
More informationTime taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Authors M A Ismail, E Okpo, S Baguley, A Butt, D Brawley, I Tonna 4 University of Aberdeen, MBChB Office, School
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationResearch Article Causes of Death in HIV Patients and the Evolution of an AIDS Hospice:
Hindawi Publishing Corporation AIDS Research and Treatment Volume 2012, Article ID 390406, 7 pages doi:10.1155/2012/390406 Research Article Causes of Death in HIV Patients and the Evolution of an AIDS
More informationHIV A 2017 Update Bill Rooney MD SCOR Global Life
NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationORIGINAL ARTICLE. See Editorial on Page 1003
LIVER TRANSPLANTATION 15:1133-1141, 2009 ORIGINAL ARTICLE The Model for End-Stage Liver Disease Score Is the Best Prognostic Factor in Human Immunodeficiency Virus 1 Infected Patients with End-Stage Liver
More informationObjective: Specific Aims:
Title: Retention to Care of HIV pregnant females in Kumasi, Ghana Brown Faculty: Aadia Rana, MD. Assistant Professor of Medicine in Division of Infectious Diseases, Awewura Kwara, Assistant Professor of
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationTime to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study
DOI: 10.1111/hiv.12201 ORIGINAL RESEARCH Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study L Deconinck, 1,2,5 Y Yazdanpanah,
More informationJournal of Infectious Diseases Advance Access published March 23, CD28-Negative CD4+ and CD8+ T-cells in ART-Naive HIV-Infected Adults
Journal of Infectious Diseases Advance Access published March 23, 2012 1 CD28-Negative CD4+ and CD8+ T-cells in ART-Naive HIV-Infected Adults Enrolled in ACTG Studies Katherine Tassiopoulos 1, Alan Landay
More informationABSTRACT Background It is unclear whether there are differences
INITIAL PLASMA HIV-1 RNA LEVELS AND PROGRESSION TO AIDS IN WOMEN AND MEN TIMOTHY R. STERLING, M.D., DAVID VLAHOV, PH.D., JACQUIE ASTEMBORSKI, M.H.S., DONALD R. HOOVER, PH.D., M.P.H., JOSEPH B. MARGOLICK,
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationCascade of medical care to HIV-infected patients in Europe. Cristina Mussini
Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment
More informationAntiviral Therapy 2012; 17:1 8 (doi: /IMP1939)
Antiviral Therapy 2012; 17:1 8 (doi: 10.3851/IMP1939) Original article Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal
More informationSupplementary Material*
Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected
More information